Research supported by the Accelerating Medicines Partnership (AMP) on Rheumatoid Arthritis and Systemic Lupus Erythematosus (RA/SLE) provides new insights into tissue damage for these autoimmune conditions. Findings include the identification of novel molecular signatures related to immune system signaling in kidney cells that may reflect their active role in disease process; molecular targets, including specific white blood cells, for potential treatment in lupus nephritis; and specific types of fibroblasts and white blood cells that are involved in rheumatoid arthritis.

The human back is a complex structure with bones, nerves, tendons, discs, and more — all places where something can go wrong and cause pain, which, for many people, becomes a long-term or chronic problem. Life stresses and other medical and mental health conditions aggravate the problem. With so many pieces, it’s hard to get a holistic view of the puzzle or pinpoint the cause of the pain. “People tend to focus on one aspect or another,” said Jeffrey Lotz, Ph.D., a medical engineer who studies back pain at the University of California, San Francisco. “Some people think it’s largely

A research team led by Dr. Makarand Risbud of Thomas Jefferson University tested whether treatment with the drugs dasatinib and quercetin would prevent disc degeneration in mice. Both drugs are senolytics, which selectively remove aged cells known as senescent cells.

HEAL-funded researcher Conor Walsh, Ph.D., and his team at the Harvard Biodesign Lab specialize in developing soft “exosuits” – wearable devices that help people with muscle weakness (for example, after a stroke) so they can regain movement and muscle strength.

A conversation between Dr. David R. Wilson, director of the NIH Tribal Health Research Office, and Dr. Lindsey A. Criswell, director of NIAMS, about information and resources for American Indians and Alaska Natives related to bone, muscle, skin, and autoimmune diseases.